{
    "title": "108_hr4512",
    "content": "The \"Medicare Prescription Drug Improvement Act\" allows negotiation of fair prices for Medicare prescription drugs on behalf of beneficiaries. Section 1860D-11 of the Social Security Act is amended to give the Secretary authority to negotiate prices with manufacturers of covered part D drugs to ensure beneficiaries pay the lowest possible price. This is in line with the goal of providing quality care and containing costs under Medicare. Section 1860D-2(b) of the Social Security Act is amended to repeal paragraph (3), and there are conforming amendments made to various subsections within the Act. Section 1860D-2(b) of the Social Security Act is amended to repeal paragraph (3) and make conforming amendments. Section 1860D-4(a)(4)(B) is amended to provide notice of prescription drug benefits in relation to the annual out-of-pocket threshold. Section 1860D-14 of the Social Security Act is amended to redesignate subparagraphs and update references in various paragraphs. Section 1860D-14 of the Social Security Act is amended to update references in various paragraphs, including redesignating subsections (a)(1)(D) and (a)(2)(E) to (a)(1)(C) and (a)(2)(D). The effective date for these amendments is retroactive to the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. TITLE II--IMPORTATION OF PRESCRIPTION DRUGS\n\nThis title is known as the \"Pharmaceutical Market Access Act of 2004\" and it focuses on the importation of prescription drugs. The Federal Food, Drug, and Cosmetic Act is amended to nullify certain amendments made by Public Law 108-173, specifically in sections 804, 301, and 303. Additionally, the Importation of Prescription Drugs under section 804 is further amended. The Pharmaceutical Market Access Act of 2003 requires compliance with specific sections of the Federal Food, Drug, and Cosmetic Act for imported products. Pharmacists, wholesalers, and qualifying individuals are included in the requirements. The Pharmaceutical Market Access Act of 2003 mandates compliance with certain sections of the Federal Food, Drug, and Cosmetic Act for imported products, excluding qualifying individuals. Amendments include changes to subsection (d) such as removing paragraphs (3) and (10), modifying paragraph (5) by eliminating the requirement for the importer's professional license number, and adjusting paragraph (6) by adding language related to subsection (e) requirements. Amendments to the Pharmaceutical Market Access Act of 2003 include changes to subsection (e) requiring testing by the importer of the covered product. Amendments to the Pharmaceutical Market Access Act of 2003 now exempt wholesalers from testing requirements for counterfeit-resistant technologies, and remove limitations on Secretary-designated products to protect public health. The Secretary will conduct a study on imports permitted under subsection (a), evaluating importer compliance with regulations and the incidence of misbranded or adulterated shipments compared to domestic prescription drug shipments. The Pharmaceutical Market Access Act of 2003 requires the timely reporting of misbranded or adulterated prescription drugs within the United States. The definition of a qualifying individual is clarified, excluding pharmacists and wholesalers. Subsections (l) and (m) are removed. SEC. 203 of the Federal Food, Drug, and Cosmetic Act requires drug packaging to comply with counterfeit-resistant technologies to prevent counterfeiting. The Secretary must mandate drug packaging to integrate overt optically variable counterfeit-resistant technologies or equivalent secure technologies visible to the naked eye, similar to those used for securing US currency. The Secretary must mandate drug packaging to integrate overt optically variable counterfeit-resistant technologies or equivalent secure technologies visible to the naked eye, similar to those used for securing US currency. Drugs must be manufactured and distributed in a secure environment and incorporate non-visible covert security features. Packaging standards require multiple elements to incorporate specified technologies, including blister packs, shrink wrap, labels, seals, bottles, and boxes. Shipments must include a label on the shipping container with the specified technologies. The shipping container must have labels with specified technologies for officials to verify shipment authenticity. Chain of custody procedures apply, including auditing and database access for governmental agencies."
}